Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Yıl: 2022 Cilt: 33 Sayı: 10 Sayfa Aralığı: 862 - 873 Metin Dili: İngilizce DOI: 10.5152/tjg.2022.21271 İndeks Tarihi: 25-10-2022

Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey

Öz:
Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir + ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. World Health Organization. WHO model list of essential medicines. Available at: https ://ww w.who .int/ medic ines/ publi catio ns/es senti almed icine s/en/ . Accessed December 12, 2019.
  • 2. Abdel-Aziz F, Habib M, Mohamed MK, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 2000;32(1):111-115. [CrossRef]
  • 3. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting angtivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol. 2017;29(6):686-693. [CrossRef]
  • 4. Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV- 001 Study. Dig Dis Sci. 2008;53(3):809-814. [CrossRef]
  • 5. Mücke MM, Herrmann E, Mücke VT, Graf C, Zeuzem S, Vermehren J. Efficacy and safety of dğrect-acting antivirals for hepatitis C in the elderly: a systematic review and meta-analysis. Liver Int. 2019;39(9):1652-1660. [CrossRef]
  • 6. Yang Z, Zhuang L, Yang L, et al. Efficacy and safety of peginterferon plus ribavirin for patients aged ≥65 years with chronic hepatitis C: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38(4):440-450. [CrossRef]
  • 7. Kinchen VJ, Cox AL, Bailey JR. Can broadly neutralizing monoclonal antibodies lead to a hepatitis C virus vaccine ? Trends Microbiol. 2018;26(10):854-864. [CrossRef]
  • 8. Jhaveri MA, Manne V, Kowdley KV. Chronic hepatitis C in elderly patients: current evidence with direct-acting antivirals. Drugs Aging. 2018;35(2):117-122. [CrossRef]
  • 9. Rodríguez-Osorio I, Mena A, Meijide H, et al. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One. 2019;14(6):e0217052. [CrossRef]
  • 10. Patel A, Backstedt DW, Abidali H, Choi M, Pedersen M, Seetharam A. Effectiveness and tolerability of direct acting antiviral therapy for hepatitis C in a real world elderly cohort. Clin Gastroenterol Hepatol. 2017;15(4):603-604. [CrossRef]
  • 11. Villani R, Donatiello I, Barone F, et al. Efficacy and safety of directacting antivirals in elderly with hepatitis C: results from a retrospective cohort study. J Gerontol Geriatr. 2018;66:46-55.
  • 12. Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct-acting antiviral treatment and clinical significance of durg-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856-865. [CrossRef]
  • 13. Tozun N, Ozdogan O, Cakaloglu Y, et. al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-1026. [CrossRef]
  • 14. Cabalak M, Bal T. Effectiveness of oral direct acting antivirals in elderly chronic hepatitis C patients: real world data. Turk Geriatr Derg;23(4):473-481.
  • 15. World Health Organization (WHO). Definition of an older or elderly person from 2012. Available at: http: //www .who. int/h ealth info/ surve y/age ingde fnold er/en /. Accessed February 18, 2013 [Ref list].
  • 16. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-293. [CrossRef]
  • 17. Available at: https ://ct ep.ca ncer. gov/p rotoc oldev elopm ent/e lectr onic_ appli catio ns/do cs/CT CAE_v 5_Qui ck_Re feren ce_8. 5x11. pdf. Accessed December 09, 2019.
  • 18. American Association for the Study of Liver Disease Practice guidelines. Available at: https ://ww w.aas ld.or g/pub licat ions/ pract ice-g uidel ines. Accessed December 27, 2019.
  • 19. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513-21, 521.e1, 521.e1-521.e6. [CrossRef]
  • 20. Pan CQ, Gayam V, Rabinovich C, et al. Efficacy of direct-acting antivirals for chronic hepatitis C in a large cohort of older adults in the United States. J Am Geriatr Soc. 2020;68(2):379-387. [CrossRef]
  • 21. Dultz G, Müller T, Petersen J, et al. Effectiveness and safety of direct-acting antiviral combination therapies for treatment of hepatitis C virus in elderly patients: results from the German hepatitis C registry. Drugs Aging. 2018;35(9):843-857. [CrossRef]
  • 22. Qureshi K, Petersen T, Andres J. Hepatitis C treatment differences in elderly patients: single-center retrospective study. Ann Pharmacother. 2020;54(2):113-121. [CrossRef]
  • 23. Conti F, Brillanti S, Buonfiglioli F, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24(6):454-463. [CrossRef]
  • 24. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173-1181. [CrossRef]
  • 25. Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to directacting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis. J Hepatol. 2019;71(3):473-485. [CrossRef]
  • 26. Yen YH, Chen CH, Hung CH, et al. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data. PLoS One. 2019;14(10):e0222605. [CrossRef]
  • 27. Sugiura A, Joshita S, Umemura T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving directacting antivirals. J Viral Hepat. 2018;25(12):1462-1471. [CrossRef]
  • 28. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727-733. [CrossRef]
  • 29. EASL Recommendations on treatment of hepatitis C 2018. European Association for the study of the liver. J Hepatol. 2018;69(2):461- 511. [CrossRef]
  • 30. American Association for the Study of Liver Diseases. IDSA HCV guidance panel. hepatitis C guidance 2018 uptodate: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10): 1477-1492.
  • 31. Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66(10):1844-1852. [CrossRef]
  • 32. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762-768. [CrossRef]
  • 33. Kao JH, Ahn SH, Chien RN, et al. Urgency to treat pagtients with chronic hepatitis C in Asia. J Gastroenterol Hepatol. 2017;32(5):966- 974. [CrossRef]
  • 34. Bal T, Cabalak M. Sofosbuvir and ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Ann Med Res. 2020;27(8):2067. [CrossRef]
  • 35. Medeiros T, Salviato CM, do Rosário NF, et al. Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience. Int J Clin Pharm. 2017;39(6):1304- 1311. [CrossRef]
  • 36. Reid M, Price JC, Tien PC. Hepatitis C virus infection in the older patient. Infect Dis Clin North Am. 2017;31(4):827-838. [CrossRef]
  • 37. Dultz G, Müller T, Petersen J, et al. Leberstiftungs-GmbH Deutschland. Drugs Aging. 2018;35(9):843-857. [CrossRef]
  • 38. Sherigar JM, Gayam V, Khan A, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2017;29(7):767-776. [CrossRef]
  • 39. Bräu N, Bini EJ, Stancic S, Finch DA, Aytaman A. Severe migraine headaches are caused by ribavirin but not by interferon alpha-2b in combination therapy for chronic hepatitis C. J Hepatol. 2003;38(6):871-872. [CrossRef]
  • 40. Lens S, Fernández I, Rodríguez-Tajes S, et al. Interferon-free therapy in elderly patients with advanced liver disease. Am J Gastroenterol. 2017;112(9):1400-1409. [CrossRef]
  • 41. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649-659. [CrossRef]
  • 42. Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus related cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64(4):790-799. [CrossRef]
  • 43. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64(4):763- 765. [CrossRef]
  • 44. Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother. 2017;18(17):1867-1874. [CrossRef]
  • 45. Collins BH, Holzknecht ZE, Lynn KA, et al. Association of agedependent liver injury and fibrosis with immune cell populations. Liver Int. 2013;33(8):1175-1186. [CrossRef]
  • 46. Wedemeyer H, Craxí A, Zuckerman E, et al. Real-world effectiveness of ombit asvir /pari tapre vir/r itona vir ± dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24(11):936-943. [CrossRef]
APA ONLEN Y, Bal T, çabalak m, Oztoprak N, Didem sarı N, Kurtaran B, Şenateş E, Gunduz A, zerdali e, KARSEN H, Batirel A, KARAALİ R, GÜNER R, Yamazhan T, köse ş, Erben N, Ince N, Koksal I, Sarıgül F, Yörük G, komur s, Kaya S, Esen Ş, Gunal O, YILDIZ I, İNAN D, Barut S, NAMIDURU M, Tosun S, Türker K, Sener A, hizel k, Baykam N, Duygu F, Akıncı E, Can G, User U, GÜL H, AKBULUT A, Celebi G, Sunnetcioglu M, KARABAY O, kumbasar karaosmanoglu h, SIRMATEL F, Tabak F (2022). Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. , 862 - 873. 10.5152/tjg.2022.21271
Chicago ONLEN YÜSÜF,Bal Tayibe,çabalak mehmet,Oztoprak Nefise,Didem sarı Nagehan,Kurtaran Behice,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Sarıgül Figen,Yörük Gülşen,komur suheyla,Kaya Sibel,Esen Şaban,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Akıncı Esragül,Can Güray,User Ulku,GÜL Hanefi Cem,AKBULUT AYHAN,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. (2022): 862 - 873. 10.5152/tjg.2022.21271
MLA ONLEN YÜSÜF,Bal Tayibe,çabalak mehmet,Oztoprak Nefise,Didem sarı Nagehan,Kurtaran Behice,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Sarıgül Figen,Yörük Gülşen,komur suheyla,Kaya Sibel,Esen Şaban,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Akıncı Esragül,Can Güray,User Ulku,GÜL Hanefi Cem,AKBULUT AYHAN,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. , 2022, ss.862 - 873. 10.5152/tjg.2022.21271
AMA ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. . 2022; 862 - 873. 10.5152/tjg.2022.21271
Vancouver ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. . 2022; 862 - 873. 10.5152/tjg.2022.21271
IEEE ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F "Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey." , ss.862 - 873, 2022. 10.5152/tjg.2022.21271
ISNAD ONLEN, YÜSÜF vd. "Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey". (2022), 862-873. https://doi.org/10.5152/tjg.2022.21271
APA ONLEN Y, Bal T, çabalak m, Oztoprak N, Didem sarı N, Kurtaran B, Şenateş E, Gunduz A, zerdali e, KARSEN H, Batirel A, KARAALİ R, GÜNER R, Yamazhan T, köse ş, Erben N, Ince N, Koksal I, Sarıgül F, Yörük G, komur s, Kaya S, Esen Ş, Gunal O, YILDIZ I, İNAN D, Barut S, NAMIDURU M, Tosun S, Türker K, Sener A, hizel k, Baykam N, Duygu F, Akıncı E, Can G, User U, GÜL H, AKBULUT A, Celebi G, Sunnetcioglu M, KARABAY O, kumbasar karaosmanoglu h, SIRMATEL F, Tabak F (2022). Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turkish Journal of Gastroenterology, 33(10), 862 - 873. 10.5152/tjg.2022.21271
Chicago ONLEN YÜSÜF,Bal Tayibe,çabalak mehmet,Oztoprak Nefise,Didem sarı Nagehan,Kurtaran Behice,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Sarıgül Figen,Yörük Gülşen,komur suheyla,Kaya Sibel,Esen Şaban,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Akıncı Esragül,Can Güray,User Ulku,GÜL Hanefi Cem,AKBULUT AYHAN,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turkish Journal of Gastroenterology 33, no.10 (2022): 862 - 873. 10.5152/tjg.2022.21271
MLA ONLEN YÜSÜF,Bal Tayibe,çabalak mehmet,Oztoprak Nefise,Didem sarı Nagehan,Kurtaran Behice,Şenateş Ebubekir,Gunduz Alper,zerdali esra,KARSEN HASAN,Batirel Ayse,KARAALİ Rıdvan,GÜNER RAHMET,Yamazhan Tansu,köse şükran,Erben Nurettin,Ince Nevin,Koksal Iftihar,Sarıgül Figen,Yörük Gülşen,komur suheyla,Kaya Sibel,Esen Şaban,Gunal Ozgur,YILDIZ ILKNUR ESEN,İNAN DİLARA,Barut Sener,NAMIDURU Mustafa,Tosun Selma,Türker Kamuran,Sener Alper,hizel kenan,Baykam Nurcan,Duygu Fazilet,Akıncı Esragül,Can Güray,User Ulku,GÜL Hanefi Cem,AKBULUT AYHAN,Celebi Guven,Sunnetcioglu Mahmut,KARABAY OĞUZ,kumbasar karaosmanoglu hayat,SIRMATEL FATMA,Tabak Fehmi Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turkish Journal of Gastroenterology, vol.33, no.10, 2022, ss.862 - 873. 10.5152/tjg.2022.21271
AMA ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turkish Journal of Gastroenterology. 2022; 33(10): 862 - 873. 10.5152/tjg.2022.21271
Vancouver ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey. Turkish Journal of Gastroenterology. 2022; 33(10): 862 - 873. 10.5152/tjg.2022.21271
IEEE ONLEN Y,Bal T,çabalak m,Oztoprak N,Didem sarı N,Kurtaran B,Şenateş E,Gunduz A,zerdali e,KARSEN H,Batirel A,KARAALİ R,GÜNER R,Yamazhan T,köse ş,Erben N,Ince N,Koksal I,Sarıgül F,Yörük G,komur s,Kaya S,Esen Ş,Gunal O,YILDIZ I,İNAN D,Barut S,NAMIDURU M,Tosun S,Türker K,Sener A,hizel k,Baykam N,Duygu F,Akıncı E,Can G,User U,GÜL H,AKBULUT A,Celebi G,Sunnetcioglu M,KARABAY O,kumbasar karaosmanoglu h,SIRMATEL F,Tabak F "Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey." Turkish Journal of Gastroenterology, 33, ss.862 - 873, 2022. 10.5152/tjg.2022.21271
ISNAD ONLEN, YÜSÜF vd. "Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey". Turkish Journal of Gastroenterology 33/10 (2022), 862-873. https://doi.org/10.5152/tjg.2022.21271